M. Janssens, J. van Smeden, G.S. Gooris, W. Bras, G. Portale, P.J. Caspers, R.J. Vreeken, T. Hankemeier, S. Kezic, R. Wolterbeek, A.P. Lavrijsen, J.A. Bouwstra
A hallmark of atopic eczema (AE) is skin barrier dysfunction. Lipids in the stratum corneum (SC), primarily ceramides, fatty acids, and cholesterol, are crucial for the barrier function, but their role in relation to AE is indistinct. Filaggrin is an epithelial barrier protein with a central role in the pathogenesis of AE. Nevertheless, the precise causes of AE-associated barrier dysfunction are largely unknown.
H. Wei, W. Pasman, C. Rubingh, S. Wopereis, M. Tienstra, J. Schroen, M. Wang, E. Verheij, J. van der Greef
The prevalence of type 2 diabetes continuously increases globally. A personalized strategy applied in the pre-diabetic stage is vital for diabetic prevention and management. The personalized diagnosis of Chinese Medicine (CM) may help to stratify the diabetics. Metabolomics is regarded as a potential platform to provide biomarkers for disease-subtypes. We designed an explorative study of 50 pre-diabetic males, combining GC-MS urine metabolomics with CM diagnosis in order to identify diagnostic biomarkers for pre-diabetic subtypes.
This talk, ultra-weak photon emission from living systems, covers three issues. The first issue deals with the detection of biological radiation. The development of photomultipliers and their general properties. The second issue deals with the developments in the evidence for photons originating from living systems from cells to human. The last issue deals with the non-linear relation between cell number and photon count (DL) and as illustration we use photon emission research in tumor biology.
Metabolites play numerous roles in the healthy and diseased body, ranging from regulating physiological processes to providing building blocks for the body. Therefore, understanding the role of metabolites is important in elucidating the etiology and pathology of diseases and finding targets for new treatment options. Rheumatoid arthritis is a complex chronic disease for which new disease management strategies are needed.
C. Hu, H. Wei, A.M. van den Hoek, M. Wang, R. van der Heijden, G. Spijksma, T.H. Reijmers, J. Bouwman, S. Wopereis, L.M. Havekes, E. Verheij, T. Hankemeier, G.W. Xu, J. van der Greef
Background Lipids are known to play crucial roles in the development of life-style related risk factors such as obesity, dyslipoproteinemia, hypertension and diabetes. The first selective cannabinoid-1 receptor blocker rimonabant, an anorectic anti-obesity drug, was frequently used in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2 with associated risk factors such as type II diabetes and dyslipidaemia in the past.
In the present experiment ultra-weak photon emission/ chemiluminescence from isolated neutrophils was recorded. It is associated with the production of reactive oxygen species (ROS) in the “respiratory burst” process which can be activated by PMA (Phorbol 12-Myristate 13-Acetate). Commonly, the reaction is demonstrated utilizing the enhancer luminol. However, with the use of highly sensitive photomultiplier equipment it is also recorded without enhancer.
H.A. van Wietmarschen, W. Dai, A.J. van der Kooij, T.H. Reijmers, Y. Schroën, M. Wang, Z. Xu, X. Wang, H. Kong, G. Xu, T. Hankemeier, J.J. Meulman, J. van der Greef
The aim is to characterize subgroups or phenotypes of rheumatoid arthritis (RA) patients using a systems biology approach. The discovery of subtypes of rheumatoid arthritis patients is an essential research area for the improvement of response to therapy and the development of personalized medicine strategies.
In this study, 39 RA patients are phenotyped using clinical chemistry measurements, urine and plasma metabolomics analysis and symptom profiles.
The Netherlands Metabolomics Centre focusses on the development of metabolomics based technologies and instrumentation to address the current and future challenges in biology, biotechnology and biomedical research in order to improve personalised health and quality of life.